SPRB

Business Context and Reporting Period

Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Spruce is a late-stage biopharmaceutical company focused on developing therapies for neurological disorders. Its primary asset is tralesinidase alfa ("TA-ERT") for Sanfilippo Syndrome Type B (MPS IIIB), which received FDA Breakthrough Therapy Designation in October 2025. The company also holds rights to tildacerfont and SPR202. In April 2025, the company executed a 1:75 reverse stock split to regain Nasdaq compliance after a temporary delisting.

Key Financial Metrics

Note: The filing indicates a subsequent private placement in October 2025 raised approximately $50.0 million, which is not reflected in the September 30, 2025 balance sheet.

Material Changes vs. Prior Period

• Revenue: Collaboration revenue dropped to zero for the three and nine months ended September 30, 2025, compared to $0.6 million and $4.2 million in the prior year periods. This is due to the full recognition of the upfront payment from the Kaken Pharmaceutical agreement in the prior year.
• Operating Expenses: Total operating expenses decreased by approximately 18% year-over-year for the nine-month period ($25.4 million vs. $36.3 million). This reduction was driven by a 55% workforce reduction in April 2025 and the discontinuation of the tildacerfont CAH development program.
• Liquidity: Cash and cash equivalents declined significantly from $38.8 million at year-end 2024 to $10.7 million at September 30, 2025, reflecting a net cash burn of $26.9 million from operations over the nine-month period.
• Debt: The company reduced its term loan principal from $1.8 million to $0.5 million during the period. Subsequently, in November 2025, the company prepaid the remaining balance in full.

Outlook, Risks, and Management Commentary

• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least 12 months following the issuance date of the financial statements. Without the October 2025 financing or additional capital, current cash is insufficient to fund operations.
• Strategic Focus: The company has shifted focus to TA-ERT for MPS IIIB, with a planned Biologics License Application (BLA) submission in Q1 2026. The tildacerfont CAH program was discontinued, though development for Major Depressive Disorder (MDD) continues in partnership with HMNC.
• Financing: In October 2025, the company closed a private placement raising approximately $50.0 million. In November 2025, the company terminated its loan agreement with Silicon Valley Bank after prepaying the outstanding balance.
• Risks: Key risks include the failure to obtain regulatory approval for TA-ERT, inability to raise additional capital, reliance on third-party manufacturers, and potential intellectual property disputes. The company also faces risks related to the U.S. government shutdown impacting FDA review timelines.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $50 million October 2025 financing combined with remaining cash to fund operations through the anticipated Q1 2026 BLA submission and potential commercial launch.
• TA-ERT Regulatory Path: Confirm the status of the FDA Type C meeting outcomes and the specific requirements for the confirmatory Phase 3 trial required for accelerated approval.
• Debt Obligations: Confirm the full repayment of the Silicon Valley Bank term loan and the absence of any remaining covenants or liens.
• Workforce Reduction Impact: Assess whether the 55% reduction in staff has impacted the company's ability to execute the accelerated development timeline for TA-ERT.
• Stock Status: Verify the current trading status on Nasdaq following the 1:75 reverse stock split and the resumption of trading in September 2025.